aid_data_record_id,sector_name,title,description,staff_comments,combined_text,success,error_message,primary_class,confidence,project_type,justification,evidence
41373,EDUCATION,Chinese Embassy donates teaching materials to Shahid Beheshti University,"On May 6th 2015, Chinese Embassy in Iran donated some Chinese books, audiovisual materials, and traditional crafts to the Shahid Beheshti University. These donated materials not only help the exhibition on the school's Culture Festival, but also help the school's Chinese teaching.","This project is NOT believed to be a duplicate of project ID#41372. Although materials are the same type, the receiving universities appear to be different. The project is NOT believed to be a duplicate of project ID#68574, which is also a Chinese donation to Shahid Beheshti University, since they are committed in different years, although the receiving agency is same.","# Sector
EDUCATION

# Title
Chinese Embassy donates teaching materials to Shahid Beheshti University

# Description
On May 6th 2015, Chinese Embassy in Iran donated some Chinese books, audiovisual materials, and traditional crafts to the Shahid Beheshti University. These donated materials not only help the exhibition on the school's Culture Festival, but also help the school's Chinese teaching.",TRUE,NA,NEUTRAL,HIGH,Social Development,Project involves donation of educational materials with no direct environmental or energy transition impact,"Donation of books, audiovisual materials, and traditional crafts for educational purposes"
85267,"INDUSTRY, MINING, CONSTRUCTION",Chinese Government provides $1.02 billion buyer’s credit loan for Second Phase of SALCO Aluminum Smelter Construction Project (Linked to Project ID#85268),"In March 2012, South Aluminum Corporation (SALCO or شرکت آلومینیوم جنوب) — a joint venture between the Iranian Mines and Mining Industries Development and Renovation Organisation (IMIDRO), an Iranian state-owned enterprise, and Ghadir Investment Company, a military-affiliated Iranian conglomerate — signed an EPC plus Financing (EPC+F) contract with China Nonferrous Metal Industry’s Foreign Engineering & Construction Company (NFC). In January 2015, NFC secured a buyer’s credit loan from an unidentified Chinese Government institution (most likely China Development Bank) to finance 85% ($1.02 billion) of the cost of the $1.2 billion (RMB 7.179 billion) general EPC contract, which was signed February 28, 2011. The borrower purchased buyer's credit insurance from Sinosure.  The purpose of this project was to construct an aluminum smelter in the Lamerd Special Economic Zone within the southern province of Fars. Construction began on December 24, 2015 and the smelter was officially inaugurated on April 3, 2020. China Eximbank also provided a loan for the construction of a 913MW Lamard Combined Cycle Power Plant to power the aluminum smelter that is run by SALCO (captured via Project ID#85268).","1. The Chinese project title is 伊朗南方铝业公司电解铝项目 or 简称“伊朗南方铝项目. The Persian project title is مجتمع صنایع آلومینیوم جنوب. 2. The SALCO website makes several references to conversations and negotiations with China Development Bank (CDB). However, AidData has not yet identified clear-cut, official evidence that it is the financier. This issue warrants further investigation.3. Under the EPC+F arrangement through which this project was financed, it appears that CDB extended a loan to the EPC contractor (NFC) but with a sovereign guarantee from the Iranian Government. However, this issue warrants further investigation.","# Sector
INDUSTRY, MINING, CONSTRUCTION

# Title
Chinese Government provides $1.02 billion buyer’s credit loan for Second Phase of SALCO Aluminum Smelter Construction Project (Linked to Project ID#85268)

# Description
In March 2012, South Aluminum Corporation (SALCO or شرکت آلومینیوم جنوب) — a joint venture between the Iranian Mines and Mining Industries Development and Renovation Organisation (IMIDRO), an Iranian state-owned enterprise, and Ghadir Investment Company, a military-affiliated Iranian conglomerate — signed an EPC plus Financing (EPC+F) contract with China Nonferrous Metal Industry’s Foreign Engineering & Construction Company (NFC). In January 2015, NFC secured a buyer’s credit loan from an unidentified Chinese Government institution (most likely China Development Bank) to finance 85% ($1.02 billion) of the cost of the $1.2 billion (RMB 7.179 billion) general EPC contract, which was signed February 28, 2011. The borrower purchased buyer's credit insurance from Sinosure.  The purpose of this project was to construct an aluminum smelter in the Lamerd Special Economic Zone within the southern province of Fars. Construction began on December 24, 2015 and the smelter was officially inaugurated on April 3, 2020. China Eximbank also provided a loan for the construction of a 913MW Lamard Combined Cycle Power Plant to power the aluminum smelter that is run by SALCO (captured via Project ID#85268).",TRUE,NA,BROWN,HIGH,Other,"Primary purpose is construction of an aluminum smelter, which is a high-emission industrial facility without clear energy efficiency focus","Construction of aluminum smelter, no mention of energy efficiency improvements or renewable energy integration"
65293,"AGRICULTURE, FORESTRY, FISHING",Bank of China contributes EUR 100 million to EUR 1.05 billion syndicated loan for Bright Food Group's acquisition of a 76.7331% stake in Tnuva,"On March 18, 2015, Bright Food Group Co., a Chinese state-owned enterprise (SOE), signed a EUR 1.05 billion syndicated loan agreement with a group of 10 banks to facilitate its acquisition of a 76.7331% (controlling) stake in Tnuva Food Industries, Agricultural Co-Operative Association in Israel Ltd. and Tnuva Central Co-Operative for the Marketing of Agricultural Produce in Israel Ltd., an Israeli food (production, distribution, and marketing) company. The Bank of China (BOC) Shanghai Branch was the lead arranger and contributed EUR 100 million to the syndicate loan. The other lenders provided the remaining EUR 905 million. The other lenders were HSBC, JPMorgan Chase & Co., Hang Seng Bank Limited, the Royal Bank of Scotland (RBS), ING Group N.V., Rabobank, Standard Chartered PLC, BNP Paribas S.A., and Barclays Bank Plc. The borrowing terms of the loan are unknown. However, it is known that EUR 600 millionwas provided in the form of a term loan and EUR 450 million was provided in the form a bridge loan. The EUR 600 million term loan was guaranteed by Bright Food and had a maturity date of March 18, 2018.  The Bright Food Group began seeking a syndicated loan to finance the acquisition of a majority share in Tnuva in May 2014, albeit only for the euro equivalent of USD 800 million. Bright Food had announced a preliminary deal with British private equity house Apax Partners LLP (APAX.UL), the majority owner of Tnuva, for Bright Food's acquisition of a 56% stake on May 22, 2014. At this time, negotiations were still ongoing with Israeli firm Mivtach Shamir Holdings, which held a 21% stake in Tnuva and had the right to sell its stake together with Apax. Bright Food considered bringing in Chinese state-supported private equity firm Sailing Capital Management as a partner to buy Mivtach's stake before to securing the syndicated loan.  On March 31, 2015, Bright Food Group's officially acquired 76.7331% equity in Tnuva. The acquisition was especially notable because Tnuva was, at the time, Israel's largest food company, and the acquisition itself was largest in the history of the Israeli food industry. The acquisition gave Bright Food, a major dairy producer, access to new production technology and products.","1. The Chinese project title is 收购以色列马克西姆农药项目 or 代表进出口银行关于16.8亿美元银团贷款给中国化工农化总公司用于收购一家以色列上市公司的融资项目.2. Tnuva, or Tenuvah, (Hebrew: תנובה‎, fruit or produce) was an Israeli food processing cooperative (co-op) owned by the kibbutzim (collective farms) and moshavim (agricultural communities) that historically specialized in milk and dairy products. Tnuva is the largest food manufacturer in Israel; its sales account for 70% of the country's dairy market as well as sales of meat, eggs and packaged food (see 'Chinese state company buys controlling stake in Tnuva'; 'Tnuva'; and pg.257 of 'Bright Food (Group) Co., Ltd. Prospectus for the tenth issue of ultra-short-term financing bonds in 2016( 光明食品（集团）有限公司 2016 年度第十期超短期融资券募集说明书').3. While a specific maturity date is known (March 18, 2018), it is only known for the €600 million EUR was provided in the form of a term loan, and there is no specific breakdown of the BOC's contribution to that loan (there is only broad knowledge of BOC's €100 million EUR contribution to the entire syndicated loan). To avoid coding a wrong maturity period (as the €450 million EUR may have a different maturity) AidData has not coded a maturity period. However, since a guarantee was provided for at least the term loan (it is not clear if the bridge loan received the loan), AidData has left Bright Food as an accountable agency (see pg.67 and 73 of 'Bright Food Singapore Holdings Pte. Ltd. Offering Circular dated 12 July 2017').","# Sector
AGRICULTURE, FORESTRY, FISHING

# Title
Bank of China contributes EUR 100 million to EUR 1.05 billion syndicated loan for Bright Food Group's acquisition of a 76.7331% stake in Tnuva

# Description
On March 18, 2015, Bright Food Group Co., a Chinese state-owned enterprise (SOE), signed a EUR 1.05 billion syndicated loan agreement with a group of 10 banks to facilitate its acquisition of a 76.7331% (controlling) stake in Tnuva Food Industries, Agricultural Co-Operative Association in Israel Ltd. and Tnuva Central Co-Operative for the Marketing of Agricultural Produce in Israel Ltd., an Israeli food (production, distribution, and marketing) company. The Bank of China (BOC) Shanghai Branch was the lead arranger and contributed EUR 100 million to the syndicate loan. The other lenders provided the remaining EUR 905 million. The other lenders were HSBC, JPMorgan Chase & Co., Hang Seng Bank Limited, the Royal Bank of Scotland (RBS), ING Group N.V., Rabobank, Standard Chartered PLC, BNP Paribas S.A., and Barclays Bank Plc. The borrowing terms of the loan are unknown. However, it is known that EUR 600 millionwas provided in the form of a term loan and EUR 450 million was provided in the form a bridge loan. The EUR 600 million term loan was guaranteed by Bright Food and had a maturity date of March 18, 2018.  The Bright Food Group began seeking a syndicated loan to finance the acquisition of a majority share in Tnuva in May 2014, albeit only for the euro equivalent of USD 800 million. Bright Food had announced a preliminary deal with British private equity house Apax Partners LLP (APAX.UL), the majority owner of Tnuva, for Bright Food's acquisition of a 56% stake on May 22, 2014. At this time, negotiations were still ongoing with Israeli firm Mivtach Shamir Holdings, which held a 21% stake in Tnuva and had the right to sell its stake together with Apax. Bright Food considered bringing in Chinese state-supported private equity firm Sailing Capital Management as a partner to buy Mivtach's stake before to securing the syndicated loan.  On March 31, 2015, Bright Food Group's officially acquired 76.7331% equity in Tnuva. The acquisition was especially notable because Tnuva was, at the time, Israel's largest food company, and the acquisition itself was largest in the history of the Israeli food industry. The acquisition gave Bright Food, a major dairy producer, access to new production technology and products.",TRUE,NA,NEUTRAL,HIGH,Financial Services,"The project involves a syndicated loan for an acquisition in the food industry, which does not have a direct environmental or energy transition impact","Syndicated loan for acquisition of food company stake, no direct environmental or energy transition components mentioned"
92412,HEALTH,Bank of China contributes $100 million to $2.5 billion syndicated loan tranche (‘Tranche A’) for Teva Pharmaceutical to acquire global generics business and certain other assets of Allergan plc (Linked to Project ID#92415 and ID#92417),"On November 16, 2015, a syndicate of banks signed a $5 billion term loan credit agreement with Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH). The borrower was expected to use the proceeds of the $5 billion loan to acquire the global generics business and certain other assets of Allergan plc. The term loan credit agreement provides for two tranches of term loans.   The first tranche of $2.5 billion (Tranche A) carried a maturity date of November 16, 2018, and  an interest rate of LIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). The second tranche of $2.5 billion (Tranche B) carried a maturity date of November 16, 2020 and an interest rate of LIBOR plus a margin ranging from 1.125% to 1.500% (based on Teva’s credit rating from time to time). Principal installments of $250 million, $250 million, $500 million and $500 million under the second tranche were due and payable on the first, second, third and fourth anniversaries, respectively, of the funding of the term loan credit agreement, with the balance due at maturity. Funding of the loans under the term loan credit agreement was subject to various conditions, including the acquisition being consummated substantially contemporaneously with the borrowing. Participants in Tranche A include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; Scotiabank (Ireland) Limited; and Scotiabank Europe plc. Bank of China contributed $100 million to Tranche A, which is captured via Project ID#92412.   Participants in Tranche B include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; and Scotiabank (Ireland) Limited. Bank of China contributed $100 million to Tranche B, which is captured via Project ID#92415.   On November 16, 2015, Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH) also entered into a $4.5 billion senior unsecured revolving credit agreement with a syndicate of banks. Under the revolving credit agreement, loans and letters of credit will be available from time to time for approximately five years from the signing date for general corporate purposes, including permitted acquisitions. Loans under the five-year, Revolving Credit Agreement carried interest at LIBOR/EURIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). Participants in the syndicate included Bank of America Merrill Lynch International Limited, Barclays Bank PLC, BNP Paribas, Citibank, N.A., London Branch, Credit Suisse Securities (USA) LLC, HSBC Bank plc, Mizuho Bank, Ltd., Morgan Stanley Senior Funding, Inc., RBC Capital Markets and Sumitomo Mitsui Banking Corporation, as Bookrunners and Mandated Lead Arrangers, Banco Bilbao Vizcaya Argentaria, S.A. New York Branch, Bank of China (Luxembourg) S.A., Commerzbank AG, New York Branch, Intesa Sanpaolo S.P.A., Lloyds Bank plc, PNC Bank, National Association, The Toronto-Dominion Bank, The Bank of Tokyo-Mitsubishi UFJ, Ltd., The Bank of Nova Scotia and Scotiabank Europe plc, as Mandated Lead Arrangers, and Crédit Industriel et Commercial, London Branch and Crédit Industriel et Commercial, New York Branch, as Lead Arrangers, and Citibank, N.A. Bank of China’s contributed $200 million to the $4.5 billion senior unsecured revolving credit agreement, which is captured via Project ID#92417.   In August 2016, Teva Pharmaceutical Industries Ltd announced that it had completed its acquisition of Allergan plc’s generics business (Actavis Generics) for $40 billion.","1. Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Until 2020, Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed by US-based Pfizer. Overall, Teva is the 18th largest pharmaceutical company in the world. Teva's facilities are located in Israel, North America, Europe, Australia, and South America. Teva shares are listed on the Tel Aviv Stock Exchange. The company is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). 2. Teva Pharmaceutical Industries Limited. Is an Israeli company registered under no 52-0013-954, the registered address of which is at Har Hozvim, Jerusalem, Israel. Teva Pharmaceutical USA, INC. is a Delaware corporation, the principal office of which is at 1090 Horsham Road, North Wales, Pennsylvania, United States of America. Teva Pharmaceutical Finance Netherlands III B.V. is a besloten vennootschap incorporated under the laws of the Netherlands, with its official seat (statutaire zetel) in Amsterdam, the Netherlands and the registered address of which is Piet Heinkade 107, 1019GM Amsterdam, registered with the Dutch trade register under number 855546876. Teva Finance Services B.V. is a Curaçao company registered under no. 105859 (0), the registered address of which is at Schout Bij Nacht Doormanweg 40, Curaçao. TEVA Finance Services II B.V. is a Curaçao company registered under no. 119570 (0), the registered address of which is at Schout Bij Nacht Doormanweg 40, Curaçao. Teva Capital Services Switzerland GMBH is a company organized under the laws of Switzerland, registered under number CHE-113.868.008. 3. The term loan agreement can be accessed in its entirety via https://www.sec.gov/Archives/edgar/data/818686/000119312515380854/d67104dex991.htm.  The senior unsecured revolving credit agreement can be accessed in its entirety via https://www.sec.gov/Archives/edgar/data/818686/000119312515380854/d67104dex992.htm. 4. AidData has estimated the all-in interest rate (1.7935%) of Tranche A by adding 1.1875% (the midpoint between 1.000% and 1.375%) to average 6-month LIBOR (0.606%) in November 2015.  AidData has estimated the all-in interest rate (1.9185%) of Tranche B by adding 1.3125% (the midpoint between 1.125% and 1.500%) to average 6-month LIBOR (0.606%) in November 2015.  AidData has estimated the all-in interest rate (1.7935%) of the revolving credit facility by adding 1.1875% to average 6-month LIBOR (0.606%) in November 2015.","# Sector
HEALTH

# Title
Bank of China contributes $100 million to $2.5 billion syndicated loan tranche (‘Tranche A’) for Teva Pharmaceutical to acquire global generics business and certain other assets of Allergan plc (Linked to Project ID#92415 and ID#92417)

# Description
On November 16, 2015, a syndicate of banks signed a $5 billion term loan credit agreement with Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH). The borrower was expected to use the proceeds of the $5 billion loan to acquire the global generics business and certain other assets of Allergan plc. The term loan credit agreement provides for two tranches of term loans.   The first tranche of $2.5 billion (Tranche A) carried a maturity date of November 16, 2018, and  an interest rate of LIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). The second tranche of $2.5 billion (Tranche B) carried a maturity date of November 16, 2020 and an interest rate of LIBOR plus a margin ranging from 1.125% to 1.500% (based on Teva’s credit rating from time to time). Principal installments of $250 million, $250 million, $500 million and $500 million under the second tranche were due and payable on the first, second, third and fourth anniversaries, respectively, of the funding of the term loan credit agreement, with the balance due at maturity. Funding of the loans under the term loan credit agreement was subject to various conditions, including the acquisition being consummated substantially contemporaneously with the borrowing. Participants in Tranche A include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; Scotiabank (Ireland) Limited; and Scotiabank Europe plc. Bank of China contributed $100 million to Tranche A, which is captured via Project ID#92412.   Participants in Tranche B include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; and Scotiabank (Ireland) Limited. Bank of China contributed $100 million to Tranche B, which is captured via Project ID#92415.   On November 16, 2015, Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH) also entered into a $4.5 billion senior unsecured revolving credit agreement with a syndicate of banks. Under the revolving credit agreement, loans and letters of credit will be available from time to time for approximately five years from the signing date for general corporate purposes, including permitted acquisitions. Loans under the five-year, Revolving Credit Agreement carried interest at LIBOR/EURIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). Participants in the syndicate included Bank of America Merrill Lynch International Limited, Barclays Bank PLC, BNP Paribas, Citibank, N.A., London Branch, Credit Suisse Securities (USA) LLC, HSBC Bank plc, Mizuho Bank, Ltd., Morgan Stanley Senior Funding, Inc., RBC Capital Markets and Sumitomo Mitsui Banking Corporation, as Bookrunners and Mandated Lead Arrangers, Banco Bilbao Vizcaya Argentaria, S.A. New York Branch, Bank of China (Luxembourg) S.A., Commerzbank AG, New York Branch, Intesa Sanpaolo S.P.A., Lloyds Bank plc, PNC Bank, National Association, The Toronto-Dominion Bank, The Bank of Tokyo-Mitsubishi UFJ, Ltd., The Bank of Nova Scotia and Scotiabank Europe plc, as Mandated Lead Arrangers, and Crédit Industriel et Commercial, London Branch and Crédit Industriel et Commercial, New York Branch, as Lead Arrangers, and Citibank, N.A. Bank of China’s contributed $200 million to the $4.5 billion senior unsecured revolving credit agreement, which is captured via Project ID#92417.   In August 2016, Teva Pharmaceutical Industries Ltd announced that it had completed its acquisition of Allergan plc’s generics business (Actavis Generics) for $40 billion.",TRUE,NA,NEUTRAL,HIGH,Financial Services,"The project involves financial services (syndicated loan) for a pharmaceutical acquisition, with no direct environmental or energy transition impact","Syndicated loan for pharmaceutical company acquisition, general corporate purposes"
92415,HEALTH,Bank of China contributes $100 million to $2.5 billion syndicated loan tranche (‘Tranche B’) for Teva Pharmaceutical to acquire global generics business and certain other assets of Allergan plc (Linked to Project ID#92412 and ID#92417),"On November 16, 2015, a syndicate of banks signed a $5 billion term loan credit agreement with Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH). The borrower was expected to use the proceeds of the $5 billion loan to acquire the global generics business and certain other assets of Allergan plc. The term loan credit agreement provides for two tranches of term loans.     The first tranche of $2.5 billion (Tranche A) carried a maturity date of November 16, 2018, and an interest rate of LIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). The second tranche of $2.5 billion (Tranche B) carried a maturity date of November 16, 2020 and an interest rate of LIBOR plus a margin ranging from 1.125% to 1.500% (based on Teva’s credit rating from time to time). Principal installments of $250 million, $250 million, $500 million and $500 million under the second tranche were due and payable on the first, second, third and fourth anniversaries, respectively, of the funding of the term loan credit agreement, with the balance due at maturity. Funding of the loans under the term loan credit agreement was subject to various conditions, including the acquisition being consummated substantially contemporaneously with the borrowing. Participants in Tranche A include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; Scotiabank (Ireland) Limited; and Scotiabank Europe plc. Bank of China contributed $100 million to Tranche A, which is captured via Project ID#92412.     Participants in Tranche B include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; and Scotiabank (Ireland) Limited. Bank of China contributed $100 million to Tranche B, which is captured via Project ID#92415.     On November 16, 2015, Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH) also entered into a $4.5 billion senior unsecured revolving credit agreement with a syndicate of banks. Under the revolving credit agreement, loans and letters of credit will be available from time to time for approximately five years from the signing date for general corporate purposes, including permitted acquisitions. Loans under the five-year, Revolving Credit Agreement carried interest at LIBOR/EURIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). Participants in the syndicate included Bank of America Merrill Lynch International Limited, Barclays Bank PLC, BNP Paribas, Citibank, N.A., London Branch, Credit Suisse Securities (USA) LLC, HSBC Bank plc, Mizuho Bank, Ltd., Morgan Stanley Senior Funding, Inc., RBC Capital Markets and Sumitomo Mitsui Banking Corporation, as Bookrunners and Mandated Lead Arrangers, Banco Bilbao Vizcaya Argentaria, S.A. New York Branch, Bank of China (Luxembourg) S.A., Commerzbank AG, New York Branch, Intesa Sanpaolo S.P.A., Lloyds Bank plc, PNC Bank, National Association, The Toronto-Dominion Bank, The Bank of Tokyo-Mitsubishi UFJ, Ltd., The Bank of Nova Scotia and Scotiabank Europe plc, as Mandated Lead Arrangers, and Crédit Industriel et Commercial, London Branch and Crédit Industriel et Commercial, New York Branch, as Lead Arrangers, and Citibank, N.A. Bank of China’s contributed $200 million to the $4.5 billion senior unsecured revolving credit agreement, which is captured via Project ID#92417.   In August 2016, Teva Pharmaceutical Industries Ltd announced that it had completed its acquisition of Allergan plc’s generics business (Actavis Generics) for $40 billion.","1. Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Until 2020, Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed by US-based Pfizer. Overall, Teva is the 18th largest pharmaceutical company in the world. Teva's facilities are located in Israel, North America, Europe, Australia, and South America. Teva shares are listed on the Tel Aviv Stock Exchange. The company is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). 2. Teva Pharmaceutical Industries Limited. Is an Israeli company registered under no 52-0013-954, the registered address of which is at Har Hozvim, Jerusalem, Israel. Teva Pharmaceutical USA, INC. is a Delaware corporation, the principal office of which is at 1090 Horsham Road, North Wales, Pennsylvania, United States of America. Teva Pharmaceutical Finance Netherlands III B.V. is a besloten vennootschap incorporated under the laws of the Netherlands, with its official seat (statutaire zetel) in Amsterdam, the Netherlands and the registered address of which is Piet Heinkade 107, 1019GM Amsterdam, registered with the Dutch trade register under number 855546876. Teva Finance Services B.V. is a Curaçao company registered under no. 105859 (0), the registered address of which is at Schout Bij Nacht Doormanweg 40, Curaçao. TEVA Finance Services II B.V. is a Curaçao company registered under no. 119570 (0), the registered address of which is at Schout Bij Nacht Doormanweg 40, Curaçao. Teva Capital Services Switzerland GMBH is a company organized under the laws of Switzerland, registered under number CHE-113.868.008. 3. The term loan agreement can be accessed in its entirety via https://www.sec.gov/Archives/edgar/data/818686/000119312515380854/d67104dex991.htm.  The senior unsecured revolving credit agreement can be accessed in its entirety via https://www.sec.gov/Archives/edgar/data/818686/000119312515380854/d67104dex992.htm. 4. AidData has estimated the all-in interest rate (1.7935%) of Tranche A by adding 1.1875% (the midpoint between 1.000% and 1.375%) to average 6-month LIBOR (0.606%) in November 2015.  AidData has estimated the all-in interest rate (1.9185%) of Tranche B by adding 1.3125% (the midpoint between 1.125% and 1.500%) to average 6-month LIBOR (0.606%) in November 2015.  AidData has estimated the all-in interest rate (1.7935%) of the revolving credit facility by adding 1.1875% to average 6-month LIBOR (0.606%) in November 2015","# Sector
HEALTH

# Title
Bank of China contributes $100 million to $2.5 billion syndicated loan tranche (‘Tranche B’) for Teva Pharmaceutical to acquire global generics business and certain other assets of Allergan plc (Linked to Project ID#92412 and ID#92417)

# Description
On November 16, 2015, a syndicate of banks signed a $5 billion term loan credit agreement with Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH). The borrower was expected to use the proceeds of the $5 billion loan to acquire the global generics business and certain other assets of Allergan plc. The term loan credit agreement provides for two tranches of term loans.     The first tranche of $2.5 billion (Tranche A) carried a maturity date of November 16, 2018, and an interest rate of LIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). The second tranche of $2.5 billion (Tranche B) carried a maturity date of November 16, 2020 and an interest rate of LIBOR plus a margin ranging from 1.125% to 1.500% (based on Teva’s credit rating from time to time). Principal installments of $250 million, $250 million, $500 million and $500 million under the second tranche were due and payable on the first, second, third and fourth anniversaries, respectively, of the funding of the term loan credit agreement, with the balance due at maturity. Funding of the loans under the term loan credit agreement was subject to various conditions, including the acquisition being consummated substantially contemporaneously with the borrowing. Participants in Tranche A include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; Scotiabank (Ireland) Limited; and Scotiabank Europe plc. Bank of China contributed $100 million to Tranche A, which is captured via Project ID#92412.     Participants in Tranche B include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; and Scotiabank (Ireland) Limited. Bank of China contributed $100 million to Tranche B, which is captured via Project ID#92415.     On November 16, 2015, Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH) also entered into a $4.5 billion senior unsecured revolving credit agreement with a syndicate of banks. Under the revolving credit agreement, loans and letters of credit will be available from time to time for approximately five years from the signing date for general corporate purposes, including permitted acquisitions. Loans under the five-year, Revolving Credit Agreement carried interest at LIBOR/EURIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). Participants in the syndicate included Bank of America Merrill Lynch International Limited, Barclays Bank PLC, BNP Paribas, Citibank, N.A., London Branch, Credit Suisse Securities (USA) LLC, HSBC Bank plc, Mizuho Bank, Ltd., Morgan Stanley Senior Funding, Inc., RBC Capital Markets and Sumitomo Mitsui Banking Corporation, as Bookrunners and Mandated Lead Arrangers, Banco Bilbao Vizcaya Argentaria, S.A. New York Branch, Bank of China (Luxembourg) S.A., Commerzbank AG, New York Branch, Intesa Sanpaolo S.P.A., Lloyds Bank plc, PNC Bank, National Association, The Toronto-Dominion Bank, The Bank of Tokyo-Mitsubishi UFJ, Ltd., The Bank of Nova Scotia and Scotiabank Europe plc, as Mandated Lead Arrangers, and Crédit Industriel et Commercial, London Branch and Crédit Industriel et Commercial, New York Branch, as Lead Arrangers, and Citibank, N.A. Bank of China’s contributed $200 million to the $4.5 billion senior unsecured revolving credit agreement, which is captured via Project ID#92417.   In August 2016, Teva Pharmaceutical Industries Ltd announced that it had completed its acquisition of Allergan plc’s generics business (Actavis Generics) for $40 billion.",TRUE,NA,NEUTRAL,HIGH,Financial Services,"The project involves financial services (syndicated loan) for a pharmaceutical acquisition, with no direct environmental or energy transition impact","Syndicated loan for pharmaceutical company acquisition, no energy or environmental components mentioned"
92417,HEALTH,Bank of China contributes $200 million to $4.5 billion syndicated revolving credit facility for Teva Pharmaceutical to acquire global generics business and certain other assets of Allergan plc (Linked to Project ID#92412 and ID#92415),"On November 16, 2015, a syndicate of banks signed a $5 billion term loan credit agreement with Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH). The borrower was expected to use the proceeds of the $5 billion loan to acquire the global generics business and certain other assets of Allergan plc. The term loan credit agreement provides for two tranches of term loans.   The first tranche of $2.5 billion (Tranche A) carried a maturity date of November 16, 2018, and  an interest rate of LIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). The second tranche of $2.5 billion (Tranche B) carried a maturity date of November 16, 2020 and an interest rate of LIBOR plus a margin ranging from 1.125% to 1.500% (based on Teva’s credit rating from time to time). Principal installments of $250 million, $250 million, $500 million and $500 million under the second tranche were due and payable on the first, second, third and fourth anniversaries, respectively, of the funding of the term loan credit agreement, with the balance due at maturity. Funding of the loans under the term loan credit agreement was subject to various conditions, including the acquisition being consummated substantially contemporaneously with the borrowing. Participants in Tranche A include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; Scotiabank (Ireland) Limited; and Scotiabank Europe plc. Bank of China contributed $100 million to Tranche A, which is captured via Project ID#92412.   Participants in Tranche B include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; and Scotiabank (Ireland) Limited. Bank of China contributed $100 million to Tranche B, which is captured via Project ID#92415.   On November 16, 2015, Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH) also entered into a $4.5 billion senior unsecured revolving credit agreement with a syndicate of banks. Under the revolving credit agreement, loans and letters of credit will be available from time to time for approximately five years from the signing date for general corporate purposes, including permitted acquisitions. Loans under the five-year, Revolving Credit Agreement carried interest at LIBOR/EURIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). Participants in the syndicate included Bank of America Merrill Lynch International Limited, Barclays Bank PLC, BNP Paribas, Citibank, N.A., London Branch, Credit Suisse Securities (USA) LLC, HSBC Bank plc, Mizuho Bank, Ltd., Morgan Stanley Senior Funding, Inc., RBC Capital Markets and Sumitomo Mitsui Banking Corporation, as Bookrunners and Mandated Lead Arrangers, Banco Bilbao Vizcaya Argentaria, S.A. New York Branch, Bank of China (Luxembourg) S.A., Commerzbank AG, New York Branch, Intesa Sanpaolo S.P.A., Lloyds Bank plc, PNC Bank, National Association, The Toronto-Dominion Bank, The Bank of Tokyo-Mitsubishi UFJ, Ltd., The Bank of Nova Scotia and Scotiabank Europe plc, as Mandated Lead Arrangers, and Crédit Industriel et Commercial, London Branch and Crédit Industriel et Commercial, New York Branch, as Lead Arrangers, and Citibank, N.A. Bank of China’s contributed $200 million to the $4.5 billion senior unsecured revolving credit agreement, which is captured via Project ID#92417.   In August 2016, Teva Pharmaceutical Industries Ltd announced that it had completed its acquisition of Allergan plc’s generics business (Actavis Generics) for $40 billion.","1. Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Until 2020, Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed by US-based Pfizer. Overall, Teva is the 18th largest pharmaceutical company in the world. Teva's facilities are located in Israel, North America, Europe, Australia, and South America. Teva shares are listed on the Tel Aviv Stock Exchange. The company is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). 2. Teva Pharmaceutical Industries Limited. Is an Israeli company registered under no 52-0013-954, the registered address of which is at Har Hozvim, Jerusalem, Israel. Teva Pharmaceutical USA, INC. is a Delaware corporation, the principal office of which is at 1090 Horsham Road, North Wales, Pennsylvania, United States of America. Teva Pharmaceutical Finance Netherlands III B.V. is a besloten vennootschap incorporated under the laws of the Netherlands, with its official seat (statutaire zetel) in Amsterdam, the Netherlands and the registered address of which is Piet Heinkade 107, 1019GM Amsterdam, registered with the Dutch trade register under number 855546876. Teva Finance Services B.V. is a Curaçao company registered under no. 105859 (0), the registered address of which is at Schout Bij Nacht Doormanweg 40, Curaçao. TEVA Finance Services II B.V. is a Curaçao company registered under no. 119570 (0), the registered address of which is at Schout Bij Nacht Doormanweg 40, Curaçao. Teva Capital Services Switzerland GMBH is a company organized under the laws of Switzerland, registered under number CHE-113.868.008. 3. The term loan agreement can be accessed in its entirety via https://www.sec.gov/Archives/edgar/data/818686/000119312515380854/d67104dex991.htm.  The senior unsecured revolving credit agreement can be accessed in its entirety via https://www.sec.gov/Archives/edgar/data/818686/000119312515380854/d67104dex992.htm. 4. AidData has estimated the all-in interest rate (1.7935%) of Tranche A by adding 1.1875% (the midpoint between 1.000% and 1.375%) to average 6-month LIBOR (0.606%) in November 2015.  AidData has estimated the all-in interest rate (1.9185%) of Tranche B by adding 1.3125% (the midpoint between 1.125% and 1.500%) to average 6-month LIBOR (0.606%) in November 2015.  AidData has estimated the all-in interest rate (1.7935%) of the revolving credit facility by adding 1.1875% to average 6-month LIBOR (0.606%) in November 2015.","# Sector
HEALTH

# Title
Bank of China contributes $200 million to $4.5 billion syndicated revolving credit facility for Teva Pharmaceutical to acquire global generics business and certain other assets of Allergan plc (Linked to Project ID#92412 and ID#92415)

# Description
On November 16, 2015, a syndicate of banks signed a $5 billion term loan credit agreement with Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH). The borrower was expected to use the proceeds of the $5 billion loan to acquire the global generics business and certain other assets of Allergan plc. The term loan credit agreement provides for two tranches of term loans.   The first tranche of $2.5 billion (Tranche A) carried a maturity date of November 16, 2018, and  an interest rate of LIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). The second tranche of $2.5 billion (Tranche B) carried a maturity date of November 16, 2020 and an interest rate of LIBOR plus a margin ranging from 1.125% to 1.500% (based on Teva’s credit rating from time to time). Principal installments of $250 million, $250 million, $500 million and $500 million under the second tranche were due and payable on the first, second, third and fourth anniversaries, respectively, of the funding of the term loan credit agreement, with the balance due at maturity. Funding of the loans under the term loan credit agreement was subject to various conditions, including the acquisition being consummated substantially contemporaneously with the borrowing. Participants in Tranche A include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; Scotiabank (Ireland) Limited; and Scotiabank Europe plc. Bank of China contributed $100 million to Tranche A, which is captured via Project ID#92412.   Participants in Tranche B include Banco Bilbao Vizcaya Argentaria, S.A. New York Branch; Bank of America Merrill Lynch International Limited; Bank of China (Luxembourg) S.A.; Barclays Bank PLC; BNP Paribas Fortis S.A/N.V.; Citibank, N.A.; Crédit Industriel et Commercial, London Branch; Crédit Industriel et Commercial, New York Branch; Credit Suisse AG, Cayman Islands Branch; Commerzbank AG, New York Branch; DNB Capital LLC; HSBC Bank PLC; Intesa Sanpaolo S.P.A.; Lloyds Bank plc; Mizrahi Tefahot Bank Limited; Mizuho Bank, Ltd.; Morgan Stanley Bank, N.A.; Morgan Stanley Senior Funding, Inc.; PNC Bank, National Association; Royal Bank of Canada; Sumitomo Mitsui Banking Corporation; TD Bank, N.A.; The Bank of Tokyo-Mitsubishi UFJ, Ltd.; and Scotiabank (Ireland) Limited. Bank of China contributed $100 million to Tranche B, which is captured via Project ID#92415.   On November 16, 2015, Teva Pharmaceutical Industries Limited and five of its subsidiaries (Teva Pharmaceutical USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V., and Teva Capital Services Switzerland GMBH) also entered into a $4.5 billion senior unsecured revolving credit agreement with a syndicate of banks. Under the revolving credit agreement, loans and letters of credit will be available from time to time for approximately five years from the signing date for general corporate purposes, including permitted acquisitions. Loans under the five-year, Revolving Credit Agreement carried interest at LIBOR/EURIBOR plus a margin ranging from 1.000% to 1.375% (based on Teva’s credit rating from time to time). Participants in the syndicate included Bank of America Merrill Lynch International Limited, Barclays Bank PLC, BNP Paribas, Citibank, N.A., London Branch, Credit Suisse Securities (USA) LLC, HSBC Bank plc, Mizuho Bank, Ltd., Morgan Stanley Senior Funding, Inc., RBC Capital Markets and Sumitomo Mitsui Banking Corporation, as Bookrunners and Mandated Lead Arrangers, Banco Bilbao Vizcaya Argentaria, S.A. New York Branch, Bank of China (Luxembourg) S.A., Commerzbank AG, New York Branch, Intesa Sanpaolo S.P.A., Lloyds Bank plc, PNC Bank, National Association, The Toronto-Dominion Bank, The Bank of Tokyo-Mitsubishi UFJ, Ltd., The Bank of Nova Scotia and Scotiabank Europe plc, as Mandated Lead Arrangers, and Crédit Industriel et Commercial, London Branch and Crédit Industriel et Commercial, New York Branch, as Lead Arrangers, and Citibank, N.A. Bank of China’s contributed $200 million to the $4.5 billion senior unsecured revolving credit agreement, which is captured via Project ID#92417.   In August 2016, Teva Pharmaceutical Industries Ltd announced that it had completed its acquisition of Allergan plc’s generics business (Actavis Generics) for $40 billion.",TRUE,NA,NEUTRAL,HIGH,Financial Services,"The project involves financial services for a pharmaceutical company's acquisition, with no direct environmental or energy transition impact","Syndicated revolving credit facility for Teva Pharmaceutical's acquisition of Allergan's generics business, general corporate purposes"
39914,HEALTH,"Chinese government donated medical equipment worth 400,000 USD to Jamaica under the Bright Journey project (linked to #39915)","In June 2013, President Xi Jinping announced that China would send ophthalmologists to the Caribbean to conduct free cataract surgeries under the ""Bright Journey"" project. On 22 May 2015, the Chinese government donated medical equipment and supplies worth of 400,000 USD to the Jamaica Ministry of Health & Wellness as part of the Bright Journey project. The donation included a set of equipment for ophthalmology surgery as well as related medication and materials.   The Bright Journey project included a donation of medical equipment, free cataract surgeries, and Kingston Public Hospital staff training. The Bright Journey team consisted of 5 doctors and 3 nurses from Beijing Tongren Hospital who performed 200 cataract surgeries for Jamaican patients. The project began on 18 May 2015 and ended on 28 May 2015.   This project is linked to project ID #39915 which captures the 200 cataract surgeries performed under the Bright Journey project.",NA,"# Sector
HEALTH

# Title
Chinese government donated medical equipment worth 400,000 USD to Jamaica under the Bright Journey project (linked to #39915)

# Description
In June 2013, President Xi Jinping announced that China would send ophthalmologists to the Caribbean to conduct free cataract surgeries under the ""Bright Journey"" project. On 22 May 2015, the Chinese government donated medical equipment and supplies worth of 400,000 USD to the Jamaica Ministry of Health & Wellness as part of the Bright Journey project. The donation included a set of equipment for ophthalmology surgery as well as related medication and materials.   The Bright Journey project included a donation of medical equipment, free cataract surgeries, and Kingston Public Hospital staff training. The Bright Journey team consisted of 5 doctors and 3 nurses from Beijing Tongren Hospital who performed 200 cataract surgeries for Jamaican patients. The project began on 18 May 2015 and ended on 28 May 2015.   This project is linked to project ID #39915 which captures the 200 cataract surgeries performed under the Bright Journey project.",TRUE,NA,NEUTRAL,HIGH,Healthcare and Education Facilities,Project focuses on healthcare services and medical equipment donation without direct environmental or energy transition impacts,"Medical equipment donation, cataract surgeries, hospital staff training, healthcare focus"
70462,"AGRICULTURE, FORESTRY, FISHING",Chinese government granted 1.4 million Jamaican dollars to the Peckham bamboo project,"In May 2015, the People's Republic of China, through its Embassy in Jamaica, granted 1.4 million Jamaican dollars to the Peckham bamboo project. On 23 June 2015, the Chinese Ambassador, Dong Xiaojun, handed over the J$1.4 million to the North West Clarendon Member of Parliament, Richard Azan. The project was also financed by J$500,000 from the Caribbean Local Economic Development Project (CARILED), a program run by the Caribbean Community (CARICOM), and 130,000 USD from the Organization of American States (OAS).   The Peckham Bamboo Project was implemented by the Clarendon Municipal Corporation under the Ministry of Industry, Investment and Commerce’s Bamboo Products Industry Project (BPIP), with oversight from the Planning Institute of Jamaica (PIOJ). The purpose of the project was to create employment and entrepreneurial opportunities through bamboo cultivation, usage, training, and production of bamboo by-products. The Chinese grant was used to acquire a state-of-the-art kiln for bamboo charcoal production. A commencement ceremony occurred on May 28, 2015, and the project was completed in 2018. Bamboo investment interest is still ongoing in the Clarendon region.  Aspects of the project include training in bamboo cultivation and by-product manufacturing methodologies and techniques, tissue culture research, supporting the development of a bamboo policy framework, facilitating organic certification of bamboo farms, and establishing a pre-processing plant.",NA,"# Sector
AGRICULTURE, FORESTRY, FISHING

# Title
Chinese government granted 1.4 million Jamaican dollars to the Peckham bamboo project

# Description
In May 2015, the People's Republic of China, through its Embassy in Jamaica, granted 1.4 million Jamaican dollars to the Peckham bamboo project. On 23 June 2015, the Chinese Ambassador, Dong Xiaojun, handed over the J$1.4 million to the North West Clarendon Member of Parliament, Richard Azan. The project was also financed by J$500,000 from the Caribbean Local Economic Development Project (CARILED), a program run by the Caribbean Community (CARICOM), and 130,000 USD from the Organization of American States (OAS).   The Peckham Bamboo Project was implemented by the Clarendon Municipal Corporation under the Ministry of Industry, Investment and Commerce’s Bamboo Products Industry Project (BPIP), with oversight from the Planning Institute of Jamaica (PIOJ). The purpose of the project was to create employment and entrepreneurial opportunities through bamboo cultivation, usage, training, and production of bamboo by-products. The Chinese grant was used to acquire a state-of-the-art kiln for bamboo charcoal production. A commencement ceremony occurred on May 28, 2015, and the project was completed in 2018. Bamboo investment interest is still ongoing in the Clarendon region.  Aspects of the project include training in bamboo cultivation and by-product manufacturing methodologies and techniques, tissue culture research, supporting the development of a bamboo policy framework, facilitating organic certification of bamboo farms, and establishing a pre-processing plant.",TRUE,NA,NEUTRAL,HIGH,Social Development,"Project focuses on social and economic development through bamboo cultivation and by-product production, without clear environmental or energy transition impacts","Purpose is to create employment and entrepreneurial opportunities, includes training and research components, funded through social development grants"
70769,EDUCATION,Hanban donated Chinese textbooks to Caribbean Maritime University,"On 29 July 2015, the Chargé d’affaires at the Embassy of the People's Republic of China in Jamaica, Xia Guoshun, donated Chinese textbooks to the Caribbean Maritime University on behalf of Hanban. The textbooks were provided to aid two Chinese teachers at the University. ",NA,"# Sector
EDUCATION

# Title
Hanban donated Chinese textbooks to Caribbean Maritime University

# Description
On 29 July 2015, the Chargé d’affaires at the Embassy of the People's Republic of China in Jamaica, Xia Guoshun, donated Chinese textbooks to the Caribbean Maritime University on behalf of Hanban. The textbooks were provided to aid two Chinese teachers at the University. ",TRUE,NA,NEUTRAL,HIGH,Social Development,Project involves donation of educational materials without direct environmental or energy transition impact,"Textbook donation to university, educational focus"
70786,EDUCATION,Hanban and the Chinese government offer a Chinese language programme to the Jamaica Constabulary Force,"In 2015, Hanban and the Chinese government introduced the Chinese language programme to the Jamaica Constabulary Force (JCF). According to the JCF 2016 Annual Report, the JCF and the People's Republic of China collaborated to deliver the first Mandarin course to 65 JCF members in 2016.   On 11 August 2017, 50 police officers from Jamaica and two police officers from Suriname were awarded certificates for a Chinese training course at National Police College of Jamaica (NPCJ). On 31 August 2018, 68 police officers from Jamaica, Trinidad and Tobago, and Suriname were awarded certificates of completion for a Chinese training course at the Jamaica Police Academy. On 2 August 2019, 78 police officers from Jamaica and two police officers from Suriname were awarded certificates of completion for a Chinese training course at the Jamaica Police Academy. These Chinese training courses help Jamaican police understand the Chinese language and culture.","The Chinese language programme and the Chinese training course at the Jamaica Police Academy may be separate programs, however they both began in 2015 and were funded by the People's Republic of China and Hanban.","# Sector
EDUCATION

# Title
Hanban and the Chinese government offer a Chinese language programme to the Jamaica Constabulary Force

# Description
In 2015, Hanban and the Chinese government introduced the Chinese language programme to the Jamaica Constabulary Force (JCF). According to the JCF 2016 Annual Report, the JCF and the People's Republic of China collaborated to deliver the first Mandarin course to 65 JCF members in 2016.   On 11 August 2017, 50 police officers from Jamaica and two police officers from Suriname were awarded certificates for a Chinese training course at National Police College of Jamaica (NPCJ). On 31 August 2018, 68 police officers from Jamaica, Trinidad and Tobago, and Suriname were awarded certificates of completion for a Chinese training course at the Jamaica Police Academy. On 2 August 2019, 78 police officers from Jamaica and two police officers from Suriname were awarded certificates of completion for a Chinese training course at the Jamaica Police Academy. These Chinese training courses help Jamaican police understand the Chinese language and culture.",TRUE,NA,NEUTRAL,HIGH,Social Development,Project focuses on language education and cultural exchange without direct environmental or energy transition impacts,"Chinese language programme for police officers, cultural understanding focus"
